Welcome to LookChem.com Sign In|Join Free
  • or

51-48-9

Post Buying Request

51-48-9 Suppliers

Recommended suppliersmore

Product FOB Price Min.Order Supply Ability Supplier
Fast Delivery T4/L-Thyroxine 51-48-9 In Stock
Cas No: 51-48-9
No Data 10 Gram 500 Kilogram/Week WUHAN CIRCLE POWDER TECHNOLOGY CO.,LTD Contact Supplier
High Quality API 99% purity Supply High Purity L-Thyroxine Powder with Best Price
Cas No: 51-48-9
USD $ 0.6-0.6 / Gram 10 Gram 600 Kilogram/Month Xi'an Faithful Biotech Co., Ltd. Contact Supplier
L-Thyroxine Manufacturer/High quality/Best price/In stock
Cas No: 51-48-9
USD $ 3.0-3.0 / Kilogram 1 Kilogram 1-100 Metric Ton/Month Dayang Chem (Hangzhou) Co.,Ltd. Contact Supplier
High purity Various Specifications L-Thyroxine CAS:51-48-9
Cas No: 51-48-9
USD $ 100.0-500.0 / Gram 1 Gram 99999 Gram/Year Hangzhou Dingyan Chem Co., Ltd Contact Supplier
L-Thyroxine Powder
Cas No: 51-48-9
USD $ 299.0-300.0 / Kilogram 1 Kilogram 300 Kilogram/Month Kono Chem Co.,Ltd Contact Supplier
High Quality 99% thyroxine (t4) 51-48-9 GMP manufacturer
Cas No: 51-48-9
USD $ 0.1-0.1 / Gram 1 Gram 100 Metric Ton/Year Xi'an Xszo Chem Co., Ltd. Contact Supplier
T4 Levothyroxine CAS#51-48-9
Cas No: 51-48-9
USD $ 2.0-3.0 / Kilogram 1 Kilogram 50 Metric Ton/Month ORCHID CHEMICAL SUPPLIES LTD Contact Supplier
Factory Supply Levothyroxine
Cas No: 51-48-9
No Data 1 1 Ality Chemical Corporation Contact Supplier
Factory supply high quality L-Thyroxine Cas 51-48-9 with favorable price
Cas No: 51-48-9
USD $ 3.0-5.0 / Gram 100 Gram 120 Kilogram/Month Wuhan Fortuna Chemical Co.,Ltd Contact Supplier
L-Thyroxine
Cas No: 51-48-9
No Data 10 Milligram Amadis Chemical Co., Ltd. Contact Supplier

51-48-9 Usage

Overview

L-thyroxine is the major hormone derived from the thyroid gland. It is synthesized via the iodination of tyrosines (monoiodotyrosine) and the coupling of iodotyrosines(diiodotyrosine)?in the thyroglobulin. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form triiodothyronine that exerts a broad spectrum of stimulatory effects on cell metabolism. It is mainly used for the treatment of hypothyroidism, goiter, chronic lymphocytic thyroiditis, myxedema coma, and stupor[1]. The thyroid gland is responsible for the synthesis, storage and release of metabolic hormones including iodine-containing thyroxine(T4) and triiodothyroxine(T3). These hormones are crucial in the regulation of many metabolic processes and are vital for normal growth and development. They are also involved in calorigenic, cardiovascular and metabolic effects. The hormones exert their effects presumably by activating gene transcription of messenger RNA and proteins. To do so, they enter the cell nucleus and bind to DNA-bound thyroid receptors, which regulate gene transcription[2, 3].

Biosynthesis

Normally, the hormones secreted by the thyroid are regulated by the hypothalamic pituitary–thyroid (HPT) axis through a negative feedback system. Low levels of circulating T4 and T3 initiate the release of thyrotropin-releasing hormone (TRH) from the hypothalamus and thyroid-stimulating hormones (TSH) from the pituitary. On interaction with its specific receptor, TSH stimulates the thyroid follicular cells to synthesis T4 and T3 and release them into the bloodstream. When circulating levels of T4 and T3 increase, they inhibit the release of TRH and TSH (i.e. negative feedback mechanism)?thereby decreasing their own production[2-5]. The predominant hormone produced by the thyroid gland is T4, with approximately 70–90 mcg of T4 and 15–30 mcg of T3 produced daily[1, 6]. The production of the T3 hormone by the thyroid gland is insufficient to meet the daily requirements of the organs in the body. Therefore, approximately80 % of the body’s required T3 comes from peripheral conversion of T4 to T3[5, 7]. Although both T4 and T3 are active, T3 is more active as thyroid receptors within the cell nucleus have a 10-fold greater affinity for T3.

Indication and dosage

Levothyroxine therapy is used in case of deficiency of the thyroid hormones in the human organism, as it happens under deficiency of thyroid, pituitary and hypothalamic glands (respectively primary, secondary and tertiary hypothyroidism). Levothyroxine is also used in the treatment of euthyroid goiter and multinodular goiter, including thyroid nodules, subacute or chronic thyroiditis, or in the case of a post-surgical deficit, or after radiometabolic treatment in patients with thyroid cancer[8-10]. For an average adult under the age of 50, the typical levothyroxine sodium dose is approximately 1.7mcg/kg/day, which is equivalent to approximately 100–125 mcg/day. Older patients or patients with cardiac disease may require less levothyroxine and doses should be titrated at intervals of 4–6 weeks. Newborns, infants and adolescents require doses greater than 1.7mcg/kg/day. The guidelines that were recently released by the American Association of Clinical Endocrinologists and American Thyroid Association task force on hypothyroidism in adults, in addition to diagnosis, include suggestions of therapy[11].

Formulations

Commercial levothyroxine oral formulations available in North America and Europe include powders for intravenous solutions, tablets (e.g. Synthroid?, Levo-T?, Levothroid?, Levoxyl?, Unithroid?, Eltroxin?, Elthyrone?, Euthyrox?, Eferox?, Berlthyrox?, Letrox?, Tirosint?), soft gel capsules (Tirosint?) and oral solutions (Eltroxin?, Tirosint? oral drops and Tirosint? oral solution in unit-dose ampules). There are advantages and disadvantages that are unique to the formulation type and not to levothyroxine per se. For instance, while tablets and capsules offer the advantage of precise dosing, solutions and liquids can be easier to swallow for children or the elderly. Formulation differences that are specific to levothyroxine also exist. The influence of pH on dissolution profiles of tablets and soft gel capsules is dissimilar[12], as well as the negative impact of coffee intake on levothyroxine absorption[13,14].

Pharmacokinetics

Absorption Levothyroxine is mainly absorbed in the small intestine, more specifically through the duodenum, jejunum and ileum[15,16]. Very little is absorbed in the stomach. Consequently, patients with shorter small intestines (bowel resection)?have reduced absorption and require higher levothyroxine doses[17]. The time to maximum concentration (Tmax) occurs at approximately 2 hours in euthyroid volunteers while it is delayed to approximately 3 hours in hypothyroid patients[18]. Food also delays Tmax[18, 19]. The bioavailability of levothyroxine is approximately 60–80 % in euthyroid volunteers[19-21]. It may be slightly higher in hypothyroid and hyperthyroid patients[20, 21], and is decreased in the presence of food from 79 % under fasted conditions to 64 % under fed conditions for a 100-mcg dose[19]. The absorption of levothyroxine appears to be influenced by gastric pH[22, 23]. Centanni et al. demonstrated that in euthyroid patients suffering from nontoxic multinodular goiter, impaired gastric acid secretion or the use of omeprazole was associated with increased dosing requirements in order to adequately suppress TSH[22]. Similarly, Sachmechi and colleagues showed that chronic lansoprazole use in hypothyroid patients also resulted in increased levothyroxine dose requirements to maintain targeted TSH levels[23]. Metabolism and elimination Although T4 is subject to multiple metabolic reactions[24-26], the main metabolic route for T4 involves deiodination reactions (removal of iodine) by deiodinase enzymes[27-29], Removal of iodine from the carbon 5 of the outer ring transforms T4 to T3, thus T4 can be regarded somewhat as a pro-hormone for T3. Deiodination of the inner ring of T4 can also occur, leading to the formation of inactive reverse T3(rT3). Approximately half of deiodinised T4 is metabolised to rT3 and half to T3[29, 30]. Both T3 and rT3 are further metabolised to diiodothyronine(T2), iodothyronamine(T1) and reverse T2 and T1[29, 30]. The daily turnover rate for T4 is approximately 10 % while it is approximately 50–70 % for T3, with a slightly faster turnover rate in normal volunteers compared with patients with primary hypothyroidism[2, 3]. This equates to a half-life for T4 of 7.5 days in hypothyroid patients and 6.2 days in euthyroid individuals, while the T3 half-life is approximately 1.4 and 1.0 days for hypothyroid and euthyroid volunteers, respectively[34]. Clearance for T4 was similar with 0.056 and 0.054 L/h in hypothyroid and euthyroid subjects, respectively[34] These values are similar to other values reported in hypothyroid patients (0.0385 L/h/70 kg)[31] and in normal control subjects(0.053 to 0.064 L/h)[32, 33].

Mechanism of action

Levothyroxine acts like the endogenous thyroid hormone thyroxine(T4, a tetra-iodinated tyrosine derivative)[1]. In the liver and kidney, T4 is converted to T3, the active metabolite. In order to increase solubility, the thyroid hormones attach to thyroid hormone binding proteins, thyroxin-binding globulin, and thyroxin-binding prealbumin(transthyretin). Transport and binding to thyroid hormone receptors in the cytoplasm and nucleus then takes place. Thus, by acting as a replacement for natural thyroxine, symptoms of thyroxine deficiency are relieved.[1]

Adverse reactions

Adverse reactions[35] may include Abdominal or stomach cramps, change in appetite, crying, diarrhea, false or unusual sense of well-being, fear or nervousness, feeling not well or unhappy, feeling of discomfort, feeling of warmth, feeling things are not real, feelings of suspicion and distrust, hair loss, headache, increased appetite, mental depression, muscle weakness, quick to react or overreact emotionally, rapidly changing moods, redness of the face, neck, arms, and occasionally, upper chest, restlessness, trouble getting pregnant, trouble sitting still, unusual tiredness or weakness, vomiting and weight gain or loss. In rare conditions, symptoms like blurred or double vision, dizziness, eye pain, lack or slowing of normal growth in children, limp or walk favoring one leg, pain in the hip or knee, seizures and severe headache may occur.

Precaution

The following tips should be kept in mind when administrate the levothyroxine[35]: Levothyroxine should not be used to treat obesity or weight problems. Dangerous side effects or death can occur from the misuse of this medicine, especially if you are taking any other weight-loss medications or appetite suppressants. Since thyroid hormone occurs naturally in the body, almost anyone can take levothyroxine. However, you may not be able to take this medicine if you have the following conditions, tell your doctor if you have an untreated or uncontrolled adrenal gland disorder, a thyroid disorder called thyrotoxicosis; or, symptoms of a heart attack (chest pain or heavy feeling, pain spreading to the jaw or shoulder, nausea, sweating, general ill feeling). You should also consult your doctor if you have a history of a thyroid nodule, heart disease, a blood clot, or a blood-clotting disorder, diabetes [insulin or oral diabetes medication doses may need to be changed when you start taking this medicine], kidney disease, anemia (lack of red blood cells), osteoporosis, or low bone mineral density, problems with your pituitary gland; or any food or drug allergies. Ask your doctor for advice if you have recently received radiation therapy with iodine (such as I-131). People who become pregnant while taking levothyroxine should not stop taking the medicine without the doctor's advice. Having low thyroid hormone levels during pregnancy could harm both mother and baby. The dose needs may be different during pregnancy.

Reference

https://www.drugbank.ca/drugs/DB00451 Haynes R, Thyroid and Antithyroid Drugs. In: Gilman AG, Rall TW, Nies AS, Taylor P [editors]. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, New York: McGraw-Hill, Inc., 1993; 1361–83. Dong BJ, Thyroid and Parathyroid Disorders. In: Herfindal ET, Gourley DR, Hart LL [editors]. Clinical Pharmacy and Therapeutics, Baltimore: Williams & Wilkins, 1992; 267–306 Pangaro LN, Physiology of the Thyroid Gland. In: Becker KL [editor]. Principles and Practice of Endocrinology and Metabolism, Philadelphia: J.B. Lippincott Company, 1990. 5. Mandel SJ, Brent GA, Larsen PR, Levothyroxine therapy in patients with thyroid disease, Ann Intern Med, 1993; 119[6]: 492–502. Cavalieri RR, Rapoport B, Impaired Peripheral Conversion of Thyroxine to Triiodothyronine, Annu Rev Med, 1977; 28:57–65. LoPresti JS, Eigen A, Kaptein E, et al., Alterations in 3,3’5’-triiodothyronine metabolism in response to propylthiouracil, dexamethasone, and thyroxine HAYS MT. Thyroid hormone and the gut. Endocrine Res 1988; 14: 203-224. LIWANPO L, HERSHMAN JM. Conditions and drugs interfering with thyroxine absorption. Best Pract Res Clin Endocrinol Metab 2009; 23: 781-792. JOHN-KALARICKAL J, PEARLMAN G, CARLSON HE. New medications which decrease levothyroxine absorption. Thyroid 2007; 17: 763-765. Garber J, Cobin R, Gharib H, et al., Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association, Thyroid, 2012; 22[12]: 1200–35 Pabla D, Akhlaghi F, Zia H, A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry, Eur J Pharm Biopharm, 2009;72[1]:105–10. Benvenga S, Bartolone L, Pappalardo M, et al., Altered intestinal absorption of L-thyroxine caused by coffee, Thyroid, 2008;18[3]:293–301. Vita R, Saraceno G, Trimarchi F, Benvenga S, A novel formulation of L-thyroxine [L-T4] reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations, Endocrine, 2013;43[1]:154–60. Hays MT, Thyroid hormone and the gut, Endocr Res, 1988;14[2–3]:203–24. Hays MT, Localization of human thyroxine absorption, Thyroid, 1991;1[3]:241–8. Stone E, Leiter LA, Lambert JR, et al., L-thyroxine absorption in patients with short bowel, J Clin Endocrinol Metab, 1984;59[1]:139–41. Benvenga S, Bartolone L, Squadrito S, et al., Delayed intestinal absorption of levothyroxine, Thyroid, 1995;5[4]:249–53. Wenzel KW, Kirschsieper HE, Aspects of the absorption of oral L-thyroxine in normal man, Metabolism, 1977;26[1]:1–8. Read DG, Hays MT, Hershman JM, Absorption of oral thyroxine in hypothyroid and normal man, J Clin Endocrinol Metab, 1970;30[6]:798–9. Hasselstr?m K, Siersbaek-Nielsen K, Lumholtz IB, et al., The bioavailability of thyroxine and 3,5,3’-triiodothyronine in normal subjects and in hyperand hypothyroid patients, Acta Endocrinol [Copenh], 1985;110[4]:486–6. Centanni M, Gargano L, Canettieri G, et al., Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis, N Engl J Med, 2006;354[17]:1787–95. Sachmechi I, Reich D, Aninyei M, et al., Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism, Endocr Pract, 2007;13[4]:345-9. Mol JA, Visser TJ. Rapid and selective inner ring deiodination of thyroxine sulfate by rat liver deiodinase, Endocrinology, 1985;117[1]:8–12. Pittman CS, Shimizu T, Burger A, Chambers Jr JB, The nondeiodinative pathways of thyroxine metabolism: 3,5,3’,5-tetraiodothyroacetic acid turnover in normal and fasting human subjects, J Clin Endocrinol Metab, 1980;50[4]:712–16. Balsam A, Sexton F, Borges M, Ingbar SH, Formation of diiodotyrosine from thyroxine. Ether-link cleavage, an alternate pathway of thyroxine metabolism, J Clin Invest, 1983;72[4]:1234–45. Braverman LE, Ingbar SH, Sterling K, Conversion of thyroxine [T4] to triiodothyronine [T3] in athyreotic human subjects, J Clin Invest, 1970;49[5]:855–64. Pittman CS, Chambers JB, Read VH, The extrathyroidal conversion rate of thyroxine to triiodothyronine in normal man, J Clin Invest, 1971;50[6]:1187–96. Robbins J, Factors altering thyroid hormone metabolism, Environ Health Perspect, 1981;38:65–70. Engler D, Merkelbach U, Steiger G, Burger AG, The monodeiodination of triiodothyronine and reverse triiodothyronine in man: a quantitative evaluation of the pathway by the use of turnover rate techniques, J Clin Endocrinol Metab, 1984;58[1]:49–61. Fish LH, Schwartz HL, Cavanaugh J, et al., Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans, N Engl J Med, 1987;316[13]:764–70. Chambers Jr J, Pittman C, Suda A, The effects of propranolol on thyroxine metabolism and triiodothyronines production in man, J Clin Pharmacol, 1982;22[2–3]:110–16. van der Heijden J, Krenning E, van Toor H, et al., Three-compartmental analysis of effects of D-propranolol on thyroid hormone Nicoloff JT, Low JC, Dussault JH, Fisher DA, Simultaneous Measurement of Thyroxine and Triiodothyronine Peripheral Turnover Kinetics in Man, J Clin Invest, 1972;51[3]:473–83 https://www.drugs.com/sfx/levothyroxine-side-effects.html

Description

L-Thyroxine is a synthetic form of the thyroid hormone thyroxine.1,2,3 In vivo, L-thyroxine (0.9 and 2.7 μg) inhibits synthesis and release of thyrotropin induced by thyrotropin-releasing hormone (Item No. 22917) from the anterior pituitary in mice.1 It also reverses decreases in levels of circulating thymic serum factor (FTS) and the number of T rosette-forming cells in an old age-induced mouse model of hypothyroidism.2,3 Formulations containing L-thyroxine have been used in the treatment of hypothyroidism.

Chemical Properties

Crystalline Solid

Originator

Synthroid,Flint,US,1953

Uses

antihypercholesterimic, thyromimetic

Uses

One of the thyroid hormones involved in the maintenance of metabolic homeostasis. Synthesized and stored as amino acid residues of thyroglobulin, the major protein component of the thyroid follicular colloid. Synthesis and secretion are regulated by the pituitary hormone (TSH). Deiodinated in peripheral tissues to the active metabolite, liothyronine. The D-form has very little activity as a thyroi d hormone, but has been used to treat hyperlipidemia.

Uses

Thyroxine is one of the thyroid hormones involved in the maintenance of metabolic homeostasis. Synthesized and stored as amino acid residues of thyroglobulin, the major protein component of the thyroid follicular colloid. Synthesis and secretion are regulated by the pituitary hormone (TSH). Deiodinated in peripheral tissues to the active metabolite, liothyronine. The D-form has very little activity as a thyroid hormone, but has been used to treat hyperlipidemia.

Indications

Effects of this drug depend heavily on dosage. In small doses, levothyroxine exhibits anabolic action. In medium doses, it stimulates growth and development of tissue, metabolism of protein, fats, and carbohydrates, increases functional activity of central nervous and cardiovascular systems, as well as kidneys and liver. In large doses, it slows the thyrotropic activity of the hypophysis and suppresses thyroid gland production. Levothyroxine is used for hypothyroidism, myxedema, thyrotoxicosis, erythyroid conditions, and cretinism.

Definition

ChEBI: The L-enantiomer of thyroxine.

Manufacturing Process

A 9.30 g portion of N-acetyl-L-diiodotyrosinamide was suspended in 100 ml of 0.05M boric acid (H3BO3) and 100 ml of 95% ethanol, and the solid was dissolved by adjusting the pH to 10.5 with 2N sodium hydroxide (NaOH). A 15% (by weight) portion of manganese sulfate monohydrate was added and the solution heated at 44°C under conditions of oxygenation while being agitated mechanically. After approximately 24 hours of incubation, the precipitated product was collected and separated from the catalyst, providing the amide of N-acetyl-L-thyroxine in 30.6% yield. On hydrolysis (removal of both amide functions), achieved by refluxing in glacial acetic acid-hydrochloric acid (approximately 2:1), L-thyroxine is obtained. It was isolated as the sodium salt, containing approximately 5 molecules of water of hydration.

Brand name

Levo-T (Alara); Levolet (Vintage); Levothroid (Lloyd); Levoxyl (Jones); Novothyrox (Genpharm); Synthroid (Abbott); Unithroid (Stevens J).

Therapeutic Function

Thyroid hormone

Pharmacokinetics

Because of its firmer binding to carrier proteins, synthetic crystalline L-T4 sodium salt (levothyroxine sodium, Synthtoid, Euthyrox) has a slower onset of action than crystalline T3 or a desiccated thyroid preparation. Its administration leads to a greater increase in serum T4 but a lesser increase in serum T3 than compared with Thyroid USP. The availability of 11 different tablet strengths, ranging from 25 to 300 μg, allows individual dosing

Chemical Synthesis

Levothyroxine, L-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl] alanine (25.1.10), is synthesized in a multi-stage synthesis from 4-hydroxy-3-iodo- 5-nitrobenzaldehyde. Reacting this with benzenesulfochloride in pyridine gives the corresponding benzenesulfonate 25.1.1, the benzenesulfonyl group of which is easily replaced with a 4-methoxyphenyloxy- group upon reaction with 4-methoxyphenol. The resulting 3-iodo-4-(4-methoxyphenoxy)benzaldehyde (25.1.2) is reacted further with N-acetylglycine in the presence of sodium acetate in a Knoevenagel reaction, in which the resulting ylidene compound cyclizes to an oxazolone derivative 25.1.3. The oxazolone ring of this compound is opened upon reaction with sodium methoxide, forming the desired cinnamic acid derivative 25.1.4. The nitro group of this product is reduced to an amino group by hydrogen in the presence of a Raney nickel catalyst, forming the corresponding amine, and subsequent diazotation and replacement of the diazo group of which with iodine gives the methyl ester of α-acetamido-3,5-diiodo-4-(4-methoxyphenoxy)crotonic acid (25.1.6). The resulting compound undergoes simultaneous reaction with hydrogen iodide and phosphorous in acetic acid, in which the double bond in the crotonic acid is reduced, and the methoxy protection is removed from the phenol ring. During this, a simultaneous hydrolysis of the acetyl group on the nitrogen atom also takes place, forming D,L-3,5-diiodothyronine (25.1.7). The amino group in this product is once again protected by the reaction with formic acid in the presence of acetic anhydride, which gives D,L-N-formyl-3,5-diiodothyronine. Separation of isomers in the resulting racemic mixture is accomplished using brucine, giving D-(+)-N-formyl-3, 5-diiodothyronine L-(+)-N-formyl-3,5-diiodothyronine (25.1.8). The protecting formyl group is hydrolyzed using hydrobromic acid, giving L-(+)-3,5-diiodothyronine (25.1.9), which undergoes direct iodination using iodine in the presence of potassium iodide in aqueous methylamine, to give the desired levothyroxine.

Purification Methods

Purification is the same as for the D-isomer above. Likely impurities are tyrosine, iodotyrosine, iodothyroxines and iodide. Dissolve it in dilute ammonia at room temperature, then crystallise it by adding di[] 546 +27.8o (c 5, EtOH). [Harrington et al. Biochem J 39 164 1945, Nahm & Siedel Chem Ber 96 1 1963, Reineke & Turner J Biol Chem 161 613 1945, Chalmers et al. J Chem Soc 3424 1949, Beilstein 14 II 378, 14 III 1566, 14 IV 2373.]
InChI:InChI=1/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m0/s1

51-48-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name L-thyroxine

1.2 Other means of identification

Product number -
Other names L-Thyroxine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:51-48-9 SDS

51-48-9Synthetic route

L-thyroxine
51-48-9

L-thyroxine

Conditions
ConditionsYield
With sodium hypochlorite; tert-butylamine; sodium iodide In methanol at 20 - 30℃; Reagent/catalyst; Solvent;100%
With iodine; methylamine; potassium iodide In water at 0 - 5℃; for 2h;95%
With iodine; potassium iodide; sodium hydroxide In water at -10 - 10℃; Reagent/catalyst; Temperature;76.7%
With water; iodine; ethylamine; potassium iodide
With ammonia; iodine; potassium iodide
L-thyroxine, sodium salt hexahydrate

L-thyroxine, sodium salt hexahydrate

L-thyroxine
51-48-9

L-thyroxine

Conditions
ConditionsYield
With hydrogenchloride In methanol; dimethyl sulfoxide96%
3,5-diiodo-l-tyrosine
300-39-0

3,5-diiodo-l-tyrosine

5,7-diiodo-1-oxaspiro[2.5]octa-4,7-dien-6-one

5,7-diiodo-1-oxaspiro[2.5]octa-4,7-dien-6-one

L-thyroxine
51-48-9

L-thyroxine

Conditions
ConditionsYield
In N,N-dimethyl-formamide at 24℃; for 16h; 0.2 M borate buffer, pH 8.0 (add. of 0.1 M NaOH);94%
3,3′-diiodothyronine
70-40-6

3,3′-diiodothyronine

L-thyroxine
51-48-9

L-thyroxine

Conditions
ConditionsYield
Stage #1: 3,3′-diiodothyronine With methylamine In methanol at 25 - 30℃;
Stage #2: With iodine In methanol at -8 - 0℃;
Stage #3: With potassium dihydrogenphosphate; sodium hydrogensulfite In methanol at 15 - 20℃;
91.2%
3,5-diiodo-l-tyrosine
300-39-0

3,5-diiodo-l-tyrosine

L-thyroxine
51-48-9

L-thyroxine

Conditions
ConditionsYield
With sodium hydroxide; dihydrogen peroxide; butan-1-ol
Multi-step reaction with 4 steps
1.1: sodium hydroxide / water / 1 h
1.2: 2 h / 20 - 40 °C
2.1: diisopropylamine / water; butan-1-ol / 2 h / 20 - 90 °C
2.2: 2 h / 20 - 30 °C
3.1: acetic acid; hydrogen iodide / 5 h / 100 °C
4.1: methylamine / methanol / 25 - 30 °C
4.2: -8 - 0 °C
4.3: 15 - 20 °C
View Scheme
N-acetyl-3,5-diiodo-L-tyrosine
1027-28-7

N-acetyl-3,5-diiodo-L-tyrosine

L-thyroxine
51-48-9

L-thyroxine

Conditions
ConditionsYield
With air; water at 37℃; Erhitzen des Reaktionsprodukts mit wss. Salzsaeure und Essigsaeure;
3,5-diiodo-l-tyrosine
300-39-0

3,5-diiodo-l-tyrosine

((7R,8S)-8-Hydroxy-5,7-diiodo-6-oxo-1-oxa-spiro[2.5]oct-4-en-2-yl)-oxo-acetic acid

((7R,8S)-8-Hydroxy-5,7-diiodo-6-oxo-1-oxa-spiro[2.5]oct-4-en-2-yl)-oxo-acetic acid

L-thyroxine
51-48-9

L-thyroxine

Conditions
ConditionsYield
at 0℃; for 0.75h; Yield given;
iodoacetamide
27059-94-5

iodoacetamide

3,5-diiodo-thyronine

3,5-diiodo-thyronine

L-thyroxine
51-48-9

L-thyroxine

Conditions
ConditionsYield
With methanol; triethylamine
1-methyl-4-nitrosobenzene
623-11-0

1-methyl-4-nitrosobenzene

3,5-diiodo-l-tyrosine
300-39-0

3,5-diiodo-l-tyrosine

dihydrogen peroxide
7722-84-1

dihydrogen peroxide

butan-1-ol
71-36-3

butan-1-ol

L-thyroxine
51-48-9

L-thyroxine

casein

casein

L-thyroxine
51-48-9

L-thyroxine

Conditions
ConditionsYield
Jodierung und anschliessende Hydrolyse;
4-Hydroxymethyl-2,6-diiodo-cyclohexa-2,5-dienone

4-Hydroxymethyl-2,6-diiodo-cyclohexa-2,5-dienone

L-thyroxine
51-48-9

L-thyroxine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 37 percent / NaBiO3 / ethyl acetate; acetic acid; H2O / 4 h
2: 94 percent / dimethylformamide / 16 h / 24 °C / 0.2 M borate buffer, pH 8.0 (add. of 0.1 M NaOH)
View Scheme
3,5-diiodo-DL-thyronine
534-51-0

3,5-diiodo-DL-thyronine

L-thyroxine
51-48-9

L-thyroxine

Conditions
ConditionsYield
Multi-step reaction with 4 steps
2: (-)-α-phenethylamine; water
3: hydrobromic acid
4: concentrated ammonia; potassium iodide; iodine
View Scheme
3.5-diiodo-N.O-diacetyl-L-tyrosine
96679-34-4

3.5-diiodo-N.O-diacetyl-L-tyrosine

L-thyroxine
51-48-9

L-thyroxine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: aq. NaOH solution
2: water; air / 37 °C / Erhitzen des Reaktionsprodukts mit wss. Salzsaeure und Essigsaeure
View Scheme
N-formyl-3,5-diiodo-DL-thyronine
94298-44-9

N-formyl-3,5-diiodo-DL-thyronine

L-thyroxine
51-48-9

L-thyroxine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: (-)-α-phenethylamine; water
2: hydrobromic acid
3: concentrated ammonia; potassium iodide; iodine
View Scheme
N-formyl-3,5-diiodo-L-thyronine
94298-44-9, 120408-14-2

N-formyl-3,5-diiodo-L-thyronine

L-thyroxine
51-48-9

L-thyroxine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: hydrobromic acid
2: concentrated ammonia; potassium iodide; iodine
View Scheme
L-tyrosine
60-18-4

L-tyrosine

L-thyroxine
51-48-9

L-thyroxine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: acetic acid; iodine monochloride
2: aq. NaOH solution; butanol-(1); aqueous hydrogen peroxide
View Scheme
Multi-step reaction with 8 steps
1: hydrogenchloride / water / 24 h / 20 °C
2: sodium hydrogencarbonate / water; tetrahydrofuran / 24 h / 20 °C
3: N-iodo-succinimide / dichloromethane / 0.67 h / 0 °C
4: N-ethyl-N,N-diisopropylamine; pyridine; copper diacetate / dichloromethane / 48 h / 20 °C / Molecular sieve
5: tetrabutyl ammonium fluoride / tetrahydrofuran / 0.33 h / 0 - 20 °C
6: Iodine monochloride; N-butylamine / dichloromethane; N,N-dimethyl-formamide / 0.33 h / 0 °C
7: lithium hydroxide / water; methanol / 1.5 h / 4 °C
8: hydrogenchloride / 1,4-dioxane / 20 °C / Inert atmosphere
View Scheme
O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-L-tyrosine disodium salt

O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-L-tyrosine disodium salt

L-thyroxine
51-48-9

L-thyroxine

Conditions
ConditionsYield
With hydrogenchloride In water at 20℃; for 1h; pH=~ 4 - 5;
thyroxine
300-30-1

thyroxine

A

L-thyroxine
51-48-9

L-thyroxine

B

dextrothyroxine
51-49-0

dextrothyroxine

Conditions
ConditionsYield
With chiral stationary phase including isopropyl-functionalized CF6 In methanol; acetic acid; triethylamine; acetonitrile at 20℃; Purification / work up;
methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(4-(4-hydroxy-3,5-diaiodophenoxy)-3,5-diaiodophenyl)propanoate
1431868-09-5

methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(4-(4-hydroxy-3,5-diaiodophenoxy)-3,5-diaiodophenyl)propanoate

L-thyroxine
51-48-9

L-thyroxine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: lithium hydroxide / water; methanol / 1.5 h / 4 °C
2: hydrogenchloride / 1,4-dioxane / 20 °C / Inert atmosphere
View Scheme
(S)-2-((tert-butoxycarbonyl)amino)-3-(4-(4-hydroxy-3,5-diaiodophenoxy)-3,5-diaiodophenyl)propanoic acid

(S)-2-((tert-butoxycarbonyl)amino)-3-(4-(4-hydroxy-3,5-diaiodophenoxy)-3,5-diaiodophenyl)propanoic acid

L-thyroxine
51-48-9

L-thyroxine

Conditions
ConditionsYield
With hydrogenchloride In 1,4-dioxane at 20℃; Inert atmosphere;
L-Tyr-OMe
1080-06-4

L-Tyr-OMe

L-thyroxine
51-48-9

L-thyroxine

Conditions
ConditionsYield
Multi-step reaction with 7 steps
1: sodium hydrogencarbonate / water; tetrahydrofuran / 24 h / 20 °C
2: N-iodo-succinimide / dichloromethane / 0.67 h / 0 °C
3: N-ethyl-N,N-diisopropylamine; pyridine; copper diacetate / dichloromethane / 48 h / 20 °C / Molecular sieve
4: tetrabutyl ammonium fluoride / tetrahydrofuran / 0.33 h / 0 - 20 °C
5: Iodine monochloride; N-butylamine / dichloromethane; N,N-dimethyl-formamide / 0.33 h / 0 °C
6: lithium hydroxide / water; methanol / 1.5 h / 4 °C
7: hydrogenchloride / 1,4-dioxane / 20 °C / Inert atmosphere
View Scheme
(S)-N-(tert-butoxycarbonyl)tyrosine methyl ester
4326-36-7

(S)-N-(tert-butoxycarbonyl)tyrosine methyl ester

L-thyroxine
51-48-9

L-thyroxine

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: N-iodo-succinimide / dichloromethane / 0.67 h / 0 °C
2: N-ethyl-N,N-diisopropylamine; pyridine; copper diacetate / dichloromethane / 48 h / 20 °C / Molecular sieve
3: tetrabutyl ammonium fluoride / tetrahydrofuran / 0.33 h / 0 - 20 °C
4: Iodine monochloride; N-butylamine / dichloromethane; N,N-dimethyl-formamide / 0.33 h / 0 °C
5: lithium hydroxide / water; methanol / 1.5 h / 4 °C
6: hydrogenchloride / 1,4-dioxane / 20 °C / Inert atmosphere
View Scheme
(S)-methyl 2-((tert-butoxycarbonyl)amino)-3-(4-hydroxy-3,5-diiodophenyl)propanoate
128781-80-6

(S)-methyl 2-((tert-butoxycarbonyl)amino)-3-(4-hydroxy-3,5-diiodophenyl)propanoate

L-thyroxine
51-48-9

L-thyroxine

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: N-ethyl-N,N-diisopropylamine; pyridine; copper diacetate / dichloromethane / 48 h / 20 °C / Molecular sieve
2: tetrabutyl ammonium fluoride / tetrahydrofuran / 0.33 h / 0 - 20 °C
3: Iodine monochloride; N-butylamine / dichloromethane; N,N-dimethyl-formamide / 0.33 h / 0 °C
4: lithium hydroxide / water; methanol / 1.5 h / 4 °C
5: hydrogenchloride / 1,4-dioxane / 20 °C / Inert atmosphere
View Scheme
C30H43I2NO6Si
1016161-91-3

C30H43I2NO6Si

L-thyroxine
51-48-9

L-thyroxine

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: tetrabutyl ammonium fluoride / tetrahydrofuran / 0.33 h / 0 - 20 °C
2: Iodine monochloride; N-butylamine / dichloromethane; N,N-dimethyl-formamide / 0.33 h / 0 °C
3: lithium hydroxide / water; methanol / 1.5 h / 4 °C
4: hydrogenchloride / 1,4-dioxane / 20 °C / Inert atmosphere
View Scheme
C21H23I2NO6
1431868-05-1

C21H23I2NO6

L-thyroxine
51-48-9

L-thyroxine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: Iodine monochloride; N-butylamine / dichloromethane; N,N-dimethyl-formamide / 0.33 h / 0 °C
2: lithium hydroxide / water; methanol / 1.5 h / 4 °C
3: hydrogenchloride / 1,4-dioxane / 20 °C / Inert atmosphere
View Scheme
3,5-diiodo L-tyrosine copper complex

3,5-diiodo L-tyrosine copper complex

L-thyroxine
51-48-9

L-thyroxine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: diisopropylamine / water; butan-1-ol / 2 h / 20 - 90 °C
1.2: 2 h / 20 - 30 °C
2.1: acetic acid; hydrogen iodide / 5 h / 100 °C
3.1: methylamine / methanol / 25 - 30 °C
3.2: -8 - 0 °C
3.3: 15 - 20 °C
View Scheme
4,4'-dimethoxydiphenyliodonium iodide
6293-71-6

4,4'-dimethoxydiphenyliodonium iodide

L-thyroxine
51-48-9

L-thyroxine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: diisopropylamine / water; butan-1-ol / 2 h / 20 - 90 °C
1.2: 2 h / 20 - 30 °C
2.1: acetic acid; hydrogen iodide / 5 h / 100 °C
3.1: methylamine / methanol / 25 - 30 °C
3.2: -8 - 0 °C
3.3: 15 - 20 °C
View Scheme
2-amino-3-(3,5-diiodo-4-(4-methoxyphenoxy)phenyl)propanoic acid
94345-95-6

2-amino-3-(3,5-diiodo-4-(4-methoxyphenoxy)phenyl)propanoic acid

L-thyroxine
51-48-9

L-thyroxine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: acetic acid; hydrogen iodide / 5 h / 100 °C
2.1: methylamine / methanol / 25 - 30 °C
2.2: -8 - 0 °C
2.3: 15 - 20 °C
View Scheme
L-Lactic acid
79-33-4

L-Lactic acid

L-Tartaric acid
87-69-4

L-Tartaric acid

L-thyroxine
51-48-9

L-thyroxine

C4H6O6*C15H11I4NO4*C3H6O3

C4H6O6*C15H11I4NO4*C3H6O3

Conditions
ConditionsYield
at 10 - 20℃; for 168h;99.5%
L-thyroxine
51-48-9

L-thyroxine

L-thyroxine sodium
55-03-8

L-thyroxine sodium

Conditions
ConditionsYield
With sodium carbonate In water Reflux;98%
Stage #1: L-thyroxine With sulfuric acid; ammonia In butan-1-ol at 5 - 65℃; for 1h; pH=8;
Stage #2: With sodium hydroxide In propan-1-ol; butan-1-ol at 25 - 50℃; pH=10;
83%
With sodium carbonate Reflux;79.2%
With sodium carbonate In propan-1-ol; water at 80 - 90℃; for 1h;68%
L-Tartaric acid
87-69-4

L-Tartaric acid

L-thyroxine
51-48-9

L-thyroxine

C4H6O6*C15H11I4NO4

C4H6O6*C15H11I4NO4

Conditions
ConditionsYield
In ethanol for 72h;96%
L-thyroxine
51-48-9

L-thyroxine

Conditions
ConditionsYield
With sodium sulfite In water at 130℃; for 2h; Sealed tube; Microwave irradiation; Green chemistry;92%
L-thyroxine
51-48-9

L-thyroxine

O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-L-tyrosine disodium salt

O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-L-tyrosine disodium salt

Conditions
ConditionsYield
With sodium hydroxide In propan-1-ol; water at 80 - 90℃;91%
With sodium hydroxide In ethanol for 0.25h; Reflux;
di-tert-butyl dicarbonate
24424-99-5

di-tert-butyl dicarbonate

L-thyroxine
51-48-9

L-thyroxine

(S)-2-((tert-butoxycarbonyl)amino)-3-(4-(4-hydroxy-3,5-diaiodophenoxy)-3,5-diaiodophenyl)propanoic acid

(S)-2-((tert-butoxycarbonyl)amino)-3-(4-(4-hydroxy-3,5-diaiodophenoxy)-3,5-diaiodophenyl)propanoic acid

Conditions
ConditionsYield
In N,N-dimethyl-formamide at 20℃; for 2h;90%
In N,N-dimethyl-formamide at 20℃; for 2h;90%
With triethylamine In N,N-dimethyl-formamide at 20℃; for 1h;50%
With sodium carbonate In dimethyl sulfoxide
With hydrogenchloride; sodium hydrogencarbonate In N-methyl-acetamide; methanol; water4.2 g (4.8 mmol, 83%)
L-thyroxine
51-48-9

L-thyroxine

2,2-dimethoxy-propane
77-76-9

2,2-dimethoxy-propane

methyl (S)-2-amino-3-(4-(4-hydroxy-3,5-diaiodophenoxy)-3,5-diaiodophenyl)propanoate hydrochloride

methyl (S)-2-amino-3-(4-(4-hydroxy-3,5-diaiodophenoxy)-3,5-diaiodophenyl)propanoate hydrochloride

Conditions
ConditionsYield
With hydrogenchloride In methanol; water87%
With hydrogenchloride In methanol; water87%
Boc-Val-ONSu
3392-12-9

Boc-Val-ONSu

L-thyroxine
51-48-9

L-thyroxine

N-(t-butoxycarbonyl)-L-valyl-L-thyroxine

N-(t-butoxycarbonyl)-L-valyl-L-thyroxine

Conditions
ConditionsYield
With triethylamine In tetrahydrofuran; water at 20℃; Condensation;85%
L-thyroxine
51-48-9

L-thyroxine

oxalic acid
144-62-7

oxalic acid

C15H11I4NO4*C2H2O4

C15H11I4NO4*C2H2O4

Conditions
ConditionsYield
In ethanol at 10 - 20℃; for 120h;82.5%
bis(trichloromethyl) carbonate
32315-10-9

bis(trichloromethyl) carbonate

L-thyroxine
51-48-9

L-thyroxine

C16H9I4NO5

C16H9I4NO5

Conditions
ConditionsYield
In tetrahydrofuran at 50℃; for 1h;80%
bis(trichloromethyl) carbonate
32315-10-9

bis(trichloromethyl) carbonate

L-thyroxine
51-48-9

L-thyroxine

L-thyroxine-N-carboxyanhydride

L-thyroxine-N-carboxyanhydride

Conditions
ConditionsYield
In tetrahydrofuran at 50℃; for 1h; Inert atmosphere;80%
L-thyroxine
51-48-9

L-thyroxine

α-(N-Trifluoroacetyl)amino-β-[3,5-diiodo-4-(3',5'-diiodo-4'-hydroxyphenoxy)phenyl] propanoic acid
73122-01-7

α-(N-Trifluoroacetyl)amino-β-[3,5-diiodo-4-(3',5'-diiodo-4'-hydroxyphenoxy)phenyl] propanoic acid

Conditions
ConditionsYield
With sodium hydrogencarbonate; trifluoroacetic acid; trifluoroacetic anhydride In water; ethyl acetate70.5%
With sodium hydrogencarbonate; trifluoroacetic acid; trifluoroacetic anhydride In water; ethyl acetate70.5%
L-thyroxine
51-48-9

L-thyroxine

ethyl iodide
75-03-6

ethyl iodide

2-(ethylamino)-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid
1021496-83-2

2-(ethylamino)-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid

Conditions
ConditionsYield
In N,N-dimethyl-formamide at 20℃; for 2h;62%
In N,N-dimethyl-formamide at 20℃; for 2h;62%
butanoic acid anhydride
106-31-0

butanoic acid anhydride

L-thyroxine
51-48-9

L-thyroxine

2-(butyrylamino)-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid
806620-06-4

2-(butyrylamino)-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃; for 0.0833333h;50%
Stage #1: L-thyroxine With triethylamine In N,N-dimethyl-formamide at 20℃; for 0.0833333h;
Stage #2: butanoic acid anhydride In N,N-dimethyl-formamide at 20℃;
45%
Stage #1: L-thyroxine With triethylamine In N,N-dimethyl-formamide at 20℃; for 0.0833333h;
Stage #2: butanoic acid anhydride In N,N-dimethyl-formamide at 20℃; for 0.75h;
45%
L-thyroxine
51-48-9

L-thyroxine

acetic anhydride
108-24-7

acetic anhydride

2-acetamido-3-[4-(4-acetoxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid
26041-53-2

2-acetamido-3-[4-(4-acetoxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid

Conditions
ConditionsYield
Stage #1: L-thyroxine With triethylamine In N,N-dimethyl-formamide at 20℃; for 0.0833333h;
Stage #2: acetic anhydride In N,N-dimethyl-formamide at 20℃;
50%
With pyridine at 0 - 23℃; for 12h; Inert atmosphere;
L-thyroxine
51-48-9

L-thyroxine

ethyl iodide
75-03-6

ethyl iodide

ethyl 2-(ethylamino)-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate
1083039-06-8

ethyl 2-(ethylamino)-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate

Conditions
ConditionsYield
Stage #1: L-thyroxine With caesium carbonate In N,N-dimethyl-formamide at 20℃; for 0.0833333h;
Stage #2: ethyl iodide In N,N-dimethyl-formamide at 20℃; for 1h;
50%
Stage #1: L-thyroxine With caesium carbonate In N,N-dimethyl-formamide at 20℃; for 0.0833333h;
Stage #2: ethyl iodide In N,N-dimethyl-formamide at 20℃;
10%
L-thyroxine
51-48-9

L-thyroxine

biotinamidocaproate N-hydroxysuccinimide ester
89889-52-1

biotinamidocaproate N-hydroxysuccinimide ester

Conditions
ConditionsYield
With sodium hydrogencarbonate In water; dimethyl sulfoxide at 20℃; Cooling with ice;42%
L-thyroxine
51-48-9

L-thyroxine

L-thyroxine sulfate

L-thyroxine sulfate

Conditions
ConditionsYield
With chlorosulfonic acid; trifluoroacetic acid at 0℃; for 0.166667h;40%
L-thyroxine
51-48-9

L-thyroxine

methyl iodide
74-88-4

methyl iodide

potassium 3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]-2-(methylamino)propanoate dihydrate
1234572-93-0

potassium 3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]-2-(methylamino)propanoate dihydrate

Conditions
ConditionsYield
Stage #1: L-thyroxine; methyl iodide In N,N-dimethyl-formamide at 20℃; for 2h;
Stage #2: With potassium carbonate In N,N-dimethyl-formamide
24%
Stage #1: L-thyroxine; methyl iodide With triiodothyronine In N,N-dimethyl-formamide at 20℃; for 2h;
Stage #2: With potassium carbonate In water; N,N-dimethyl-formamide
24%
L-thyroxine
51-48-9

L-thyroxine

O-[3,5-diiodo-4-(sulfooxy)phenyl]-3,5-diiodo-L-tyrosine sodium salt

O-[3,5-diiodo-4-(sulfooxy)phenyl]-3,5-diiodo-L-tyrosine sodium salt

Conditions
ConditionsYield
Stage #1: L-thyroxine With chlorosulfonic acid In N,N-dimethyl acetamide at 0 - 20℃; for 5h; Inert atmosphere;
Stage #2: With sodium hydrogencarbonate; sodium carbonate In N,N-dimethyl acetamide; water for 1.5h;
18%
L-thyroxine
51-48-9

L-thyroxine

O-(4-hydroxyphenyl)-3,5-diiodo-L-tyrosine
1596-67-4

O-(4-hydroxyphenyl)-3,5-diiodo-L-tyrosine

Conditions
ConditionsYield
With potassium hydroxide; palladium Hydrogenation;
With sodium tetrahydroborate; C10H8STe; D,L-dithiothreitol In aq. phosphate buffer at 37℃; for 0.5h; pH=7.5; Reagent/catalyst;
L-thyroxine
51-48-9

L-thyroxine

chloroacetyl chloride
79-04-9

chloroacetyl chloride

N-chloroacetyl-3,5,3',5'-tetraiodo-L-thyronine
97738-15-3

N-chloroacetyl-3,5,3',5'-tetraiodo-L-thyronine

Conditions
ConditionsYield
With ethyl acetate
L-thyroxine
51-48-9

L-thyroxine

dimethyl sulfate
77-78-1

dimethyl sulfate

4-(3,5-diiodo-4-methoxy-phenoxy)-3,5-diiodo-trans-cinnamic acid

4-(3,5-diiodo-4-methoxy-phenoxy)-3,5-diiodo-trans-cinnamic acid

Conditions
ConditionsYield
With sodium hydroxide

51-48-9Downstream Products

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 51-48-9